Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M Witt

Showing results (1-10 of 167) with videos related to

Pageof 17
Sort By:
Blood|May 20, 2021
A better way to monitor warfarin therapy?Daniel M Witt
JAMA Network Open|February 1, 2022
Is It Time to Reevaluate Current International Normalized Ratio Targets for Asian Patients Following Mechanical Heart Valve Replacement?Daniel M Witt
Seminars in Hematology|October 18, 2011
Initiation and reinitiation of anticoagulation therapyDaniel M Witt
Hematology/Oncology Clinics of North America|July 28, 2010
Optimizing use of current anticoagulantsDaniel M Witt
Seminars in Thrombosis and Hemostasis|August 16, 2012
Approaches to optimal dosing of vitamin K antagonistsDaniel M Witt
Annals of Internal Medicine|January 19, 2011
ACP Journal Club. Review: Positive D-dimer results predict recurrence after first unprovoked VTE regardless of test timing or cutpoint, or patient ageDaniel M Witt
Thrombosis Research|September 23, 2008
The Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service as a model of modern anticoagulant careDaniel M Witt
Annals of Internal Medicine|September 18, 2013
Review: rivaroxaban causes less fatal bleeding, but does not reduce mortality, compared with VKAsDaniel M Witt
Annals of Internal Medicine|August 23, 2012
ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PEDaniel M Witt
Annals of Internal Medicine|January 19, 2011
ACP Journal Club. Weekly INR self-testing did not reduce stroke, major bleeding, or death more than monthly clinic testingDaniel M Witt
Pageof 17

Showing results (1-10 of 167) with videos related to

Sort By:
Pageof 17
Blood|May 20, 2021
A better way to monitor warfarin therapy?Daniel M Witt
JAMA Network Open|February 1, 2022
Is It Time to Reevaluate Current International Normalized Ratio Targets for Asian Patients Following Mechanical Heart Valve Replacement?Daniel M Witt
Seminars in Hematology|October 18, 2011
Initiation and reinitiation of anticoagulation therapyDaniel M Witt
Hematology/Oncology Clinics of North America|July 28, 2010
Optimizing use of current anticoagulantsDaniel M Witt
Seminars in Thrombosis and Hemostasis|August 16, 2012
Approaches to optimal dosing of vitamin K antagonistsDaniel M Witt
Annals of Internal Medicine|January 19, 2011
ACP Journal Club. Review: Positive D-dimer results predict recurrence after first unprovoked VTE regardless of test timing or cutpoint, or patient ageDaniel M Witt
Thrombosis Research|September 23, 2008
The Kaiser Permanente Colorado Clinical Pharmacy Anticoagulation Service as a model of modern anticoagulant careDaniel M Witt
Annals of Internal Medicine|September 18, 2013
Review: rivaroxaban causes less fatal bleeding, but does not reduce mortality, compared with VKAsDaniel M Witt
Annals of Internal Medicine|August 23, 2012
ACP Journal Club: rivaroxaban and usual care had similar rates of recurrent VTE and bleeding in symptomatic PEDaniel M Witt
Annals of Internal Medicine|January 19, 2011
ACP Journal Club. Weekly INR self-testing did not reduce stroke, major bleeding, or death more than monthly clinic testingDaniel M Witt
Pageof 17